Chiron Submits Inhaled Immunosuppressant Pulminiq NDA For Lung Transplant
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Chiron is requesting a priority review for its Pulminiq NDA, submitted October 14, which would place the user fee goal date for the aerosolized cyclosporine in April.